Risankizumab: all 75 studies that test it

Page 1 of 1. Open to participants first (13), then studies with results posted, then the rest; newest registration first within each.

• Risankizumab for Refractory Perianal Fistulizing Crohn's DiseaseRecruitingNCT07872449Phase 4
• Study of Advanced Therapies for the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease or Ulcerative ColitisRecruitingNCT07697456Phase 2
• A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's DiseaseRecruitingNCT07499232Phase 3
• A Study to Assess How Intravenous and Subcutaneous Administrations of Risankizumab Moves Through the Body of Healthy Adult ParticipantsRecruitingNCT07466550Phase 1
• Utilization of a Microdevice for Psoriasis and Atopic DermatitisNot yet recruitingNCT07352566Phase 4
• Risankizumab for Fibrostenotic Crohn's Disease TreatmentNot yet recruitingNCT07177118Phase 3
• Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder ArthroplastyRecruitingNCT07138898Phase 2
• A Study to Learn More About How Risankizumab Works in Young Participants With Ulcerative ColitisRecruitingNCT07071519Phase 3
• Study of Targeted Therapies for the Treatment of Adult Participants With Active Psoriatic ArthritisRecruitingNCT06865105Phase 2
• Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's DiseaseRecruitingNCT06548542Phase 2
• Risankizumab in Children With Crohn's Disease (RisaKids)RecruitingNCT06298188Not applicable
• A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or AdalimumabRecruitingNCT06100744Phase 3
• A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's DiseaseRecruitingNCT05995353Phase 3
• Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp PsoriasisCompletedNCT05969223Phase 4Results posted
• High Dose Risankizumab for PsoriasisCompletedNCT05283135Phase 2Results posted
• Study of Subcutaneous (Injected Under the Skin) Risankizumab to Assess Change in Disease Symptoms in Adult Participants With Moderate to Severe Plaque Psoriasis With Palmoplantar InvolvementCompletedNCT04713592Phase 3Results posted
• ACTIV-5 / Big Effect Trial (BET-A) for the Treatment of COVID-19CompletedNCT04583956Phase 2Results posted
• A Study of the Safety and Efficacy of Risankizumab in Adult Participants With Plaque Psoriasis Who Have Had a Suboptimal Response to Secukinumab or IxekizumabCompletedNCT04102007Phase 3Results posted
• A Global Study Comparing Risankizumab to Placebo in Adult Participants With Moderate to Severe Hidradenitis SuppurativaCompletedNCT03926169Phase 2Results posted
• A Study to Assess Usability of Risankizumab Autoinjector Combination Product in Participants With Moderate to Severe Plaque PsoriasisCompletedNCT03875508Phase 3Results posted
• A Study to Assess Safety and Efficacy of Risankizumab Using a New Formulation in Participants With Moderate to Severe Plaque PsoriasisCompletedNCT03875482Phase 3Results posted
• A Study to Evaluate Risankizumab in Adults and Adolescents With Moderate to Severe Atopic DermatitisCompletedNCT03706040Phase 2Results posted
• A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) TherapyActive, not recruitingNCT03675308Phase 3Results posted
• A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies)CompletedNCT03671148Phase 3Results posted
• Risankizumab Versus Secukinumab for Participants With Moderate to Severe Plaque PsoriasisCompletedNCT03478787Phase 3Results posted
• A Multicenter, Randomized, Double-Blind, Placebo Controlled Induction Study to Evaluate the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Ulcerative ColitisCompletedNCT03398148Phase 2/3Results posted
• A Study to Assess the Efficacy of Risankizumab Compared to FUMADERM® in Subjects With Moderate to Severe Plaque Psoriasis Who Are Naïve to and Candidates for Systemic TherapyCompletedNCT03255382Phase 3Results posted
• A Study of the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Crohn's DiseaseCompletedNCT03105128Phase 3Results posted
• A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Crohn's Disease Who Failed Prior Biologic TreatmentCompletedNCT03104413Phase 3Results posted
• A Study to Assess the Safety and Efficacy of Risankizumab for Maintenance in Moderate to Severe Plaque Type Psoriasis ( LIMMITLESS )CompletedNCT03047395Phase 3Results posted
• A Study to Assess Efficacy and Safety of Two Different Dose Regimens of Risankizumab Administered Subcutaneously in Japanese Subjects With Generalized Pustular Psoriasis or Erythrodermic PsoriasisCompletedNCT03022045Phase 3Results posted
• BI 655066 (Risankizumab) Compared to Placebo in Japanese Patients With Moderate to Severe Chronic Plaque PsoriasisCompletedNCT03000075Phase 2Results posted
• A Study to Investigate Safety With Risankizumab in Psoriatic Arthritis Subjects Who Have Completed Week 24 Visit of Study M16-002 (NCT02719171)CompletedNCT02986373Phase 2Results posted
• BI 655066/ABBV-066/Risankizumab Compared to Placebo in Patients With Active Psoriatic ArthritisCompletedNCT02719171Phase 2Results posted
• BI 655066/ABBV-066 (Risankizumab) Compared to Active Comparator (Adalimumab) in Patients With Moderate to Severe Chronic Plaque PsoriasisCompletedNCT02694523Phase 3Results posted
• BI 655066 (Risankizumab) Compared to Placebo and Active Comparator (Ustekinumab) in Patients With Moderate to Severe Chronic Plaque PsoriasisCompletedNCT02684370Phase 3Results posted
• BI 655066 Versus Placebo & Active Comparator (Ustekinumab) in Patients With Moderate to Severe Chronic Plaque PsoriasisCompletedNCT02684357Phase 3Results posted
• BI 655066 / ABBV-066 (Risankizumab) in Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Re-treatmentCompletedNCT02672852Phase 3Results posted
• A Long Term Extension Trial of BI 655066/ABBV-066 (Risankizumab), in Patients With Moderately to Severely Active Crohn's DiseaseCompletedNCT02513459Phase 2Results posted
• Efficacy and Safety of BI 655066/ABBV-066 (Risankizumab) in Patients With Severe Persistent AsthmaCompletedNCT02443298Phase 2Results posted
• Extension Trial Assessing the Safety and Efficacy of BI 655066/ABBV-066/Risankizumab in Patients With Moderate to Severe Chronic Plaque PsoriasisCompletedNCT02203851Phase 2Results posted
• BI 655066 Dose Ranging in Psoriasis, Active Comparator UstekinumabCompletedNCT02054481Phase 2Results posted
• BI 655066 (Risankizumab) Proof of Concept Dose Finding Study in Ankylosing Spondylitis (AS)CompletedNCT02047110Phase 2Results posted
• Efficacy, Safety and Pharmacokinetics of BI 655066/ABBV-066 (Risankizumab) in Patients With Active, Moderate-to-severe Crohn's Disease.CompletedNCT02031276Phase 2Results posted
• A Study to Assess the Relative Bioavailability of Risankizumab Following Subcutaneous Administrations With a Pre-Filled Syringe or an On-Body Injector in Healthy Adult ParticipantsCompletedNCT07007091Phase 1
• A Study to Assess the Bioavailability of Risankizumab Following Subcutaneous Administration With Prefilled Pen Relative to a Prefilled Syringe in Healthy Adult ParticipantsCompletedNCT06946524Phase 1
• A Study to Assess the Relative Bioavailability of Risankizumab Following Subcutaneous Administration With On-Body Injector in Healthy Adult ParticipantsCompletedNCT06937619Phase 1
• A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to VedolizumabActive, not recruitingNCT06880744Phase 3
• A Study to Assess the Relative Bioavailability of Two Formulations of Risankizumab Following Subcutaneous Administration With Prefilled Syringes in Healthy Adult ParticipantsCompletedNCT06571266Phase 1
• A Study to Assess Pharmacokinetic Exposures Following Intravenous and Subcutaneous Administration of Risankizumab in Healthy ParticipantsCompletedNCT06487572Phase 1
• A Study to Assess the Concentrations of Risankizumab in the Breast Milk of Adult Lactating Women With Inflammatory Bowel DiseaseCompletedNCT06346288Phase 4
• A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body)CompletedNCT06333860Phase 4
• A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn's Disease.Active, not recruitingNCT06063967Phase 3
• A Study to Compare the Bioavailability of Intravenously Infused Risankizumab Manufactured by Two Different Processes in Healthy AdultsCompletedNCT06054425Phase 1
• A Study in Healthy Japanese and Caucasian Subjects to Assess the Pharmacokinetics, Safety and Tolerability of RisankizumabCompletedNCT05305222Phase 1
• A Study to Evaluate the Bioavailability of Risankizumab Following Subcutaneous Dosing in Healthy Male ParticipantsCompletedNCT05283694Phase 1
• A Study to Evaluate the Bioavailability of Risankizumab in Pre-filled Syringe or Auto-injector in Healthy Adult ParticipantsCompletedNCT05283681Phase 1
• Study of Intravenous and Subcutaneous Administration of Risankizumab in Healthy ParticipantsCompletedNCT05274100Phase 1
• Study to Evaluate the Effect of Different Warm-Up Times of Risankizumab Autoinjector (AI) on the Injection Pain Experiences in Healthy VolunteersCompletedNCT05274087Phase 1
• A Study of Intravenously (IV) Infused or Subcutaneously (SC) Injected Risankizumab in Healthy Adult Participants in ChinaCompletedNCT05268068Phase 1
• A Study of Guselkumab and Risankizumab in Healthy Participants and Participants With Psoriatic ArthritisTerminatedNCT05083078Phase 1
• Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With Subcutaneous (SC) Injection of Risankizumab Who Have Completed Participation in Study M19-977Active, not recruitingNCT04862286Phase 3
• Exploring the Effects of IL-23 Inhibition by Risankizumab on Psoriasis AutoimmunityStatus unknownNCT04722640Phase 4
• Risankizumab Long-term Remission StudyCompletedNCT04630652Phase 4
• Study Comparing Intravenous (IV)/Subcutaneous (SC) Risankizumab to IV/SC Ustekinumab to Assess Change in Crohn's Disease Activity Index (CDAI) in Adult Participants With Moderate to Severe Crohn's Disease (CD)Active, not recruitingNCT04524611Phase 3
• Study of Subcutaneous Risankizumab Injection to Assess Change in Palmoplantar Pustulosis Area and Severity Index [PPPASI] in Adult Japanese Participants With Palmoplantar PustulosisCompletedNCT04451720Phase 3
• Dose Reduction of IL17 and IL23 Inhibitors in PsoriasisCompletedNCT04340076Phase 4
• A Study to Evaluate the Effect of Intravenous (IV) Infusions of Risankizumab on Pharmacokinetics of Cytochome P450 Substrates in Adult Participants With Moderately to Severely Active Ulcerative Colitis or Crohn's DiseaseCompletedNCT04254783Phase 1
• Risankizumab Therapy Versus Placebo for Subjects With Psoriasis in the Russian FederationCompletedNCT03518047Phase 3
• A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative ColitisActive, not recruitingNCT03398135Phase 3
• A Study Comparing the Safety and Efficacy of Risankizumab to Methotrexate in Subjects With Moderate to Severe Plaque PsoriasisCompletedNCT03219437Phase 3
• A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn's DiseaseActive, not recruitingNCT03105102Phase 3
• This Study Tests the Effect of Risankizumab on the Metabolism in the Liver of Five Additional Drugs to Study Possible Drug Interactions in Patients With Psoriasis With or Without Psoriatic ArthritisCompletedNCT02772601Phase 1
• Safety, Tolerability and Pharmacokinetics of BI 655066/ABBV-066 (Risankizumab) in Healthy Asian and Caucasian Male VolunteersCompletedNCT02596217Phase 1
• Single Rising Dose Study of BI 655066 in Patients With Moderate and Severe PsoriasisCompletedNCT01577550Phase 1

← Risankizumab overview